Isocitrate Dehydrogenase 1/IDH1 Antibody (IDH1/1152) - Azide and BSA Free, Novus Biologicals™

Mouse Monoclonal Antibody

Catalog Number	Mfr. No.	Quantity
NBP247744A	Novus Biologicals NBP2477440.1MG	0.1 mg
NBP247744B	Novus Biologicals NBP2477440.2MG	0.2 mg

Description

Isocitrate Dehydrogenase 1/IDH1 Monoclonal specifically detects Isocitrate Dehydrogenase 1/IDH1 in Human samples. It is validated for Immunohistochemistry, Immunohistochemistry-Paraffin.

Specifications

• Antigen: Isocitrate Dehydrogenase 1/IDH1
• Concentration: 1.0 mg/mL
• Applications: Western Blot, Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence, CyTOF
• Conjugate: Unconjugated
• Host Species: Mouse
• Research Discipline: Stem Cell Markers
• Formulation: PBS with No Preservative
• Gene ID (Entrez): 3417
• Immunogen: Recombinant fragment (119 Amino acid residues around aa 280-420) of human IDH1 protein
• Primary or Secondary: Primary
• Content And Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Molecular Weight of Antigen: 46 kDa

• Clone: IDH1/1152
• Dilution: Western Blot : 0.5 - 1.0 ug/ml, Flow Cytometry : 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin : 0.5 - 1.0 ug/ml, Immunofluorescence : 0.5 - 1.0 ug/ml, CyTOF-ready
• Classification: Monoclonal
• Form: Purified
• Regulatory Status: RUO
• Target Species: Human
• Gene Alias: Cytosolic NADP-isocitrate dehydrogenase, EC 1.1.1.42, IDCD, IDH, IDP, IDPC, isocitrate dehydrogenase [NADP] cytoplasmic, isocitrate dehydrogenase 1 (NADP+), soluble, NADP(+)-specific ICDH, NADP-dependent isocitrate dehydrogenase, cytosolic, NADP-dependent isocitrate dehydrogenase, peroxisomal, Oxalosuccinate decarboxylase, PICD
• Gene Symbols: IDH1
• Isotype: IgG1 κ
• Purification Method: Protein A or G purified
• Test Specificity: It recognizes a 45kDa protein, which is identified as isocitrate dehydrogenase (IDH1). It belongs to the isocitrate and isopropylmalate dehydrogenases family. IDH1 catalyzes the third step of the citric acid cycle, which involves the oxidative decarboxylation of isocitrate, forming ketoglutarate and CO2 in a two-step reaction. The first step involves the oxidation of isocitrate to the intermediate oxalosuccinate, while the second step involves the production of ketoglutarate. During this process, either NADH or NADPH is produced along with CO2. Recently, an inactivating mutation of IDH1 has been implicated in glioblastoma. IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway.